FDA ex­pands la­bel for No­var­tis and Roche's block­buster, con­verts EMD Serono's NSCLC drug to full ap­proval

The FDA on Fri­day signed off on an ex­pand­ed la­bel for No­var­tis and Roche’s block­buster Xo­lair (oma­l­izum­ab) and on Thurs­day con­vert­ed the ac­cel­er­at­ed to full ap­proval for EMD Serono’s non-small cell lung can­cer drug Tep­metko (tepo­tinib).

The ex­pand­ed ap­proval for Xo­lair is based on a pos­i­tive NIH-fund­ed Phase III study, af­ter an in­ter­im look at the da­ta by the study’s da­ta man­age­ment board found that study par­tic­i­pants who re­ceived oma­l­izum­ab could con­sume high­er dos­es of peanut, egg, milk and cashew with­out al­ler­gic re­ac­tions than par­tic­i­pants who re­ceived place­bo in­jec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER